brca2 ab 1 Search Results


anti-brca2 mouse monoclonal ab-1 antibody  (Merck & Co)
90
Merck & Co anti-brca2 mouse monoclonal ab-1 antibody
( A ) Chromatograms of tumour and normal breast tissue DNA showing <t>BRCA2</t> mutation: (c.6033_6034delTT/p.Ser2012GlnfsX5) Germline DNA (GDNA) shows both mutated and wild-type alleles. Loss of the wild-type allele with retention of the mutant one is shown in the primary tumour and in passage 0 (P0) and 8 (P8) of the xenograft. ( B ): Amplification of two microsatellites (D13S260 and D13S1701) flanking BRCA2 shows loss of heterozygosity in P0. ( C ) Illustrates an anti-BRCA2 immunoprecipitation on lysates generated from tumour sample HBCX-17 and 293T cells. Western blot analysis detected full-length BRCA2 in the 293T samples and a truncated BRCA2 product of the predicted size in the tumour sample. ( D ) quantitative multiplex PCR of short fragment shows that mutated allele is duplicated whereas wild-type allele is lost.
Anti Brca2 Mouse Monoclonal Ab 1 Antibody, supplied by Merck & Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-brca2 mouse monoclonal ab-1 antibody/product/Merck & Co
Average 90 stars, based on 1 article reviews
anti-brca2 mouse monoclonal ab-1 antibody - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


( A ) Chromatograms of tumour and normal breast tissue DNA showing BRCA2 mutation: (c.6033_6034delTT/p.Ser2012GlnfsX5) Germline DNA (GDNA) shows both mutated and wild-type alleles. Loss of the wild-type allele with retention of the mutant one is shown in the primary tumour and in passage 0 (P0) and 8 (P8) of the xenograft. ( B ): Amplification of two microsatellites (D13S260 and D13S1701) flanking BRCA2 shows loss of heterozygosity in P0. ( C ) Illustrates an anti-BRCA2 immunoprecipitation on lysates generated from tumour sample HBCX-17 and 293T cells. Western blot analysis detected full-length BRCA2 in the 293T samples and a truncated BRCA2 product of the predicted size in the tumour sample. ( D ) quantitative multiplex PCR of short fragment shows that mutated allele is duplicated whereas wild-type allele is lost.

Journal: British Journal of Cancer

Article Title: Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation

doi: 10.1038/sj.bjc.6605900

Figure Lengend Snippet: ( A ) Chromatograms of tumour and normal breast tissue DNA showing BRCA2 mutation: (c.6033_6034delTT/p.Ser2012GlnfsX5) Germline DNA (GDNA) shows both mutated and wild-type alleles. Loss of the wild-type allele with retention of the mutant one is shown in the primary tumour and in passage 0 (P0) and 8 (P8) of the xenograft. ( B ): Amplification of two microsatellites (D13S260 and D13S1701) flanking BRCA2 shows loss of heterozygosity in P0. ( C ) Illustrates an anti-BRCA2 immunoprecipitation on lysates generated from tumour sample HBCX-17 and 293T cells. Western blot analysis detected full-length BRCA2 in the 293T samples and a truncated BRCA2 product of the predicted size in the tumour sample. ( D ) quantitative multiplex PCR of short fragment shows that mutated allele is duplicated whereas wild-type allele is lost.

Article Snippet: Immunoprecipitations were performed by incubating Protein G beads (Sigma, Steinheim, Germany), 1–2 mg of precleared cell lysate, and anti-BRCA2 mouse monoclonal Ab-1 antibody (dilution 1 : 200; Merck) overnight at 4°C.

Techniques: Mutagenesis, Amplification, Immunoprecipitation, Generated, Western Blot, Multiplex Assay